First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70642 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Chris Brearley und 3 weiteren Autor:innen. Beteiligte Einrichtung: tranScrip Ltd, Wokingham, Berkshire, UK. Hauptthemen laut MEDLINE: Food-Drug Interactions, Janus Kinase 1, TYK2 Kinase, Tyrosine Kinase Inhibitors. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sareum Limited.
Abstract (Originalsprache)
Aim
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants.
Methods
This first‐in‐human study randomized 95 male and female participants. Parts one and two were double‐blind, placebo‐controlled escalation designs, investigating single (5, 10, 30, 75, 150 mg) and multiple (30, 100, 75, 140 mg/day) doses of SDC‐1801 or matching placebo. Part three evaluated the FE of 75 mg SDC‐1801 in an open‐label, crossover design.
Results
There were no deaths or treatment‐related serious adverse events (AEs) following SDC‐1801, up to 150 mg; no treatment‐emergent AEs (TEAEs) were severe with non‐related headache most frequently reported. PK showed low to moderate variability and no consistent dose‐exposure relationship; T max occurred 3–5 h post‐dose with a geometric mean (GM) t 1/2 of 15.2–27.0 h. Bioavailability appeared solubility limited, with lower exposure from the higher strength capsule and modestly higher exposure in the fed state. No safety stopping criteria were met. PD assessments demonstrated anti‐inflammatory activity, with IFN‐gamma induced protein‐10 (IP‐10), high sensitivity C reactive protein (hsCRP), and signal transducer and activator of transcription (STAT3/5) phosphorylation reductions with increasing exposure giving greater inhibition. At the highest exposure, there was a clear reduction of IP‐10 levels at pre‐dose on day 9, which rebounded following drug withdrawal.
Conclusions
SDC‐1801 was well tolerated to 150 mg; all TEAEs were mild or moderate, with unrelated headache most frequently reported. The PK profile supports the potential for a once‐ or twice‐daily regimen, with evidence of target engagement for both TYK2 and JAK1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- tranScrip Ltd, Wokingham, Berkshire, UK.
- Emeritus Research, (Employed by Nucleus Network at the Time of the Study), Melbourne, Victoria, Australia.
- Sareum Limited, Cambridge, UK.
ORCID-Profile: Judi Proctor
Förderung
- Sareum Limited
Zitieren
APA
Brearley, C., Francis, S., Reader, J., & Proctor, J. (2026). First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70642
Vancouver
Brearley C, Francis S, Reader J, Proctor J. First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70642
BibTeX
@article{Brearley2026,
author = {Brearley, Chris and Francis, Sam and Reader, John and Proctor, Judi},
title = {First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70642}
}
EUVIMED